For providers
Provider resources

Resources designed to educate your practice

Browse the resources below to help you make informed decisions about the Oncodetect™ Molecular Residual Disease (MRD) test and confidently support your patient’s treatment path.
Two folders that say “Welcome Kit” sitting on an orange background.
All-in-one download

Oncodetect MRD welcome kit

Get everything your practice needs to get started with the Oncodetect MRD test, including ordering instructions, specimen handling instructions, case studies, sample reports, and more.
White paper

Oncodetect MRD test

Uncovering the hidden traces of cancer and empowering more informed cancer decisions.
Two folders that say "Oncodetect MRD test: Uncovering the Hidden Traces of Cancer and Empowering Informed Cancer Decisions" sitting on an orange background.

Forms

Test requisition form

PDF
Complete this form and fax or email it to Exact Sciences to order an Oncodetect MRD test today. You can also quickly complete this form online in our Provider Hub.

New developments

New evidence validates Oncodetect’s ability to predict recurrence

Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.

Current MRD clinical studies

By investing in robust research and building a strong network of clinical collaborations, we are committed to making MRD testing an essential tool in cancer care.

General resources

MRD educational brochure

PDF
Learn the fundamentals of Molecular Residual Disease testing and how it can benefit patients with solid tumors.*

Provider overview video

Learn about the benefits of MRD testing, the Oncodetect testing process, possible results, and more.
Video describing what molecular residual disease is, how the Oncodetect MRD test works, and the test’s use cases in cancer treatment.

Specimen instructions

Tumor tissue specimen instructions

PDF
Pathology specimen requirements and delivery instructions for tumor tissue samples.

Blood specimen instructions

PDF
Oncodetect MRD test phlebotomy and delivery instructions for the clinical lab.

Case studies and sample reports

View sample Oncodetect MRD test reports, along with case studies outlining clinical and pathological scenarios in specific use cases.
Male patient in a sweater vest smiling.

Surveillance of a stage III colorectal cancer

A 64-year-old male with no comorbidities was diagnosed with colorectal cancer and underwent surgical resection of the primary tumor.

  • Diagnosis: Colorectal cancer (CRC)
  • Surgical intervention: Resection of primary tumor
  • Post-operative findings: Positive circulating tumor DNA (ctDNA)

Surveillance of a stage II colorectal cancer

PDF
A 62-year-old male underwent resection for high-risk Stage II colorectal cancer. Post-operative molecular residual disease (MRD) was detected using a circulating tumor DNA (ctDNA) assay, indicating an elevated risk of recurrence. View sample report.

Surveillance of a stage IV colorectal cancer

PDF
A 58-year-old female with oligometastatic colorectal cancer underwent neoadjuvant FOLFOX followed by surgical resection of both the primary tumor and the metastatic lesions. View sample report.

Stage III colorectal cancer escalation

PDF
A 60-year-old female with a history of rectal bleeding was diagnosed with colorectal cancer and underwent surgery to remove the tumor. View sample report.
A doctor sitting at a desk looking at a laptop.

Ordering a test for your patients is fast and easy 

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at +1 866-662-6897.

References and footnotes

  1. The test has been validated in patients with stage II-IV colorectal cancer and Exact Sciences is currently pursuing applications in additional disease ontologies.

    2. This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.